Daily Alpha · X
· Premarket Alpha · by Buzzberg Research
Memory supply is tight today, while expanding Chinese NAND capacity is a medium-term threat.
Themes on this desk
Memory scarcity
Current bookings, contract floors and earnings revisions support pricing, while YMTC's expansion is a later competitive burden.
Bond contagion
Thinner foreign Treasury demand, rising Bund yields and wider French spreads show the duration shock broadening beyond the Fed.
China demand split
Industrial output beat while retail sales, fixed investment and property starts weakened.
Ticker heat
?
Top voices by smart followers and alpha score
Market Radar →Industry source: YMTC expansion not an immediate oversupply but a medium-to-long-term burden for incumbents
An industry source said YMTC's capacity expansion is unlikely to lead to a NAND oversupply right away, but because it is growing output and share on the back of China's domestic market, it could become a medium-to-long-term competitive burden for existing NAND makers.
it is growing output and share on the back of China's domestic market, it could become a medium to long
Frames the YMTC threat as a slow-burn share and pricing issue rather than a near-term glut, implying incumbent NAND margins face gradual erosion rather than a cliff.
Watch Confirmation: YMTC share gains continuing while NAND contract prices stay firm. Invalidation: YMTC output stalling or incumbents holding share and pricing through 2027.
Source →Memory supply sold out through 2029, DDR5 allocations cut
Serenity (@aleabitoreddit) relays Team Group GM Gerry Chen's claim that there is 'zero risk of memory prices dropping,' that module makers have been warned of drastic 2027 allocation cuts (some to 50% or less of 2026 levels), that upstream makers have sold out nearly all 2027-2028 capacity, and that DDR5 supply will come in below 80% of prior expectations. Chen reportedly expects prices to rise 20-30% quarter-over-quarter into 2027, and says Micron's 2028-2029 orders are already fully booked before its new MegaFab capacity arrives in Q4 2027 at the earliest.
- Upstream manufacturers have reportedly sold out nearly all of their 2027–2028 capacity.
If accurate, this is a multi-year pricing-power story for memory suppliers (MU, SK hynix) and a cost headwind for anyone buying DRAM, and it directly contradicts the 'AI buildout is slowing' narrative that pressured semis.
Watch Confirm via Micron and SK hynix earnings commentary on 2027-2029 bookings and contract pricing, DDR5 contract price prints, and whether module-maker allocation cuts are confirmed by a second source.
Source →Syzran refinery strike adds to Russian refining outage risk
TheValueist reports a new long-range drone strike on Rosneft's Syzran refinery (design capacity ~8.5-8.9 mtpa), noting earlier 2026 hits in May, July and August damaged AVT-5 and AVT-6 primary distillation units that handle essentially all crude processing and forced full or partial shutdowns lasting weeks; damage from the latest strike is unconfirmed.
which together handle essentially all crude processing. Those strikes previously forced full or partial shutdowns lasting weeks.
Repeated outages at a top-10 Russian refinery tighten global refined product balances and can widen refining cracks, a read-through the author flags for US refiners VLO, MPC, PSX, DK and CLMT.
Watch Confirm whether Russian authorities or trade press report actual throughput loss at Syzran; sustained product cracks and export declines would validate the read-through, a quick restart would invalidate it.
Source →Caesar Capital discloses new CRDO long at $152.92 average
Caesar Capital announced it started a new position in Credo Technology ($CRDO) at an average price of $152.92 per share, an explicit, timestamped position disclosure with a specific entry level.
Caesar Capital started a new position in Credo Technology $CRDO today at an average price of $152.92 per share 🏛️
A named account disclosing a fresh long with an exact cost basis gives a concrete reference point for CRDO positioning and a level other traders can track against; it is a directly actionable disclosed position rather than commentary.
Watch Whether CRDO holds above the $152.92 disclosed average; a sustained break below that level would signal the new position is underwater and could pressure the account's conviction.
Source →VERA eGFR slope delta of 5.0 versus placebo at 104 weeks
seedy19tron reports $VERA's eGFR slope was -0.6 on drug versus -5.6 on placebo through 104 weeks, a delta of 5.0 with p<0.0001, matching the exact Phase 2b number and replicating in 428 randomized patients.
• eGFR slope -0.6 on drug vs -5.6 pbo thru 104 wks. Delta 5.0, p<0.0001.
Exact replication of the Phase 2b eGFR effect in a larger randomized population materially de-risks the pivotal dataset and supports the author's $45+ end-of-day price expectation.
Watch Whether the stock closes at or above $45 and whether the eGFR slope figures are confirmed in the company's topline release.
Source →